Halifax, Nova Scotia--(Newsfile Corp. - August 20, 2020) - Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company"), a developer of rapid, point-of-care diagnostic tests, announces that it expects to release a report on its clinical, in-field evaluation studies for its rapid detection, COVID-19 antigen test next week. This data will be used to support the Company's submissions to Health Canada and the FDA for emergency use authorization ("EUA") approval for its COVID-19 antigen test.

The Company is reliant on third parties and testing protocols with multiple complex variables, many of which are outside of the control of the Company and can impact expected timing of results. 

The Company cautions that its COVID-19 rapid antigen test is not yet approved by the FDA or other regulatory bodies and will update the market as appropriate.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.

Investor Relations Contact:

Arlen Hansen
604 684 6730 | 1 866 684 6730
arlen@kincommunications.com